about
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibodyComplex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.Treatment of elderly patients with chronic lymphocytic leukemia.Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.Personalizing therapy for older adults with lymphoid malignancies: options and obstacles.Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyNew treatment approaches in CLL: Challenges and opportunities in the elderly.Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).Marginal zone lymphoma in elderly and geriatric patients.Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.Venetoclax and obinutuzumab in chronic lymphocytic leukemia.Aging and malignant hemopathies.Aging and blood disorders: new perspectives, new challengesGeriatric assessment in older adults with aggressive lymphoma: growing evidence and new emerging questions.Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
P50
Q27027620-646FBA74-C49D-46B9-A319-8678607046EAQ27853387-CE424274-38B0-4E24-B31D-FC7ABA2921BEQ33396737-E932CE3A-6B59-4848-A8C0-05ED47455379Q33402713-01F5D873-CF2E-4CFA-B38E-2607149E4841Q33695990-A4AD677B-7823-4688-A520-1BF6F71130CDQ36779681-523C5F37-DBAE-42E1-90C5-126B08B24237Q37174690-586040ED-4F55-459D-B414-9E89337FDA84Q37386705-5A85E4F5-347D-4D67-AE52-7E5183DE0C92Q37590956-89B5F03C-5E49-407E-A24C-A5089C3D3ED7Q37844139-2726A234-52E0-4B97-9826-DE4F4DF550E8Q37966693-DD68ACCA-A806-4D83-85F1-E8E1B6A7291BQ38214296-2D4213C3-7273-4298-B40F-B513B6AB2751Q38248969-2F14E04C-AF52-4961-8971-77008AE23841Q38380183-CB03DE78-E68A-40D6-A318-F39C7D41A187Q38601727-25025F56-3262-47B0-931C-80825CDB18F7Q38676408-2062C54A-A222-4E81-8027-EFB7D947F495Q38759420-3EE38BA4-1F7F-4149-9449-244AC0AE6A67Q38918639-6F883180-41EA-4CA2-A295-FFBFC8072C4CQ39005118-CCFE27A7-1A04-49D1-9932-381CDC5AA3AEQ39154824-A4094F4C-A59A-4321-B9BA-6E4B35ABA58CQ39176368-322BD8E8-973C-458E-AFAF-ACB9A8E65614Q41041090-156E485F-F539-43FE-ADAB-B880A2771AECQ41351036-4C84DB29-2343-46BA-8569-62A73461018DQ42348732-67BD2F0C-7CD3-4170-ADB3-B0444C52EDB7Q42573900-88FD039A-B153-49F4-A21D-DFBB8781EDF1Q42591249-735135A9-0091-4B92-918D-9813A5F1E6D0Q45201711-988A65A4-E06F-4B98-8A56-494959A35E92Q45737543-53EBAD25-EE7B-4B4F-A9D8-F48DC71163A4
P50
name
Valentin Goede
@ast
Valentin Goede
@en
Valentin Goede
@es
Valentin Goede
@fr
Valentin Goede
@nl
type
label
Valentin Goede
@ast
Valentin Goede
@en
Valentin Goede
@es
Valentin Goede
@fr
Valentin Goede
@nl
prefLabel
Valentin Goede
@ast
Valentin Goede
@en
Valentin Goede
@es
Valentin Goede
@fr
Valentin Goede
@nl